|
시장보고서
상품코드
2038975
신경성 폭식증 치료 시장 : 치료법별, 투여 경로별, 유통 채널별, 지역별Bulimia Nervosa Treatment Market, By Treatment Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
신경성 폭식증 치료 시장은 2026년에 6억 4,480만 달러로 추정되고 있으며, 2033년에 9억 6,460만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.2%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 6억 4,480만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 5.20% | 2033년 시장 규모 예측 : | 9억 6,460만 달러 |
신경성 폭식증(과식증)은 단기간에 많은 양의 음식을 섭취하는(과식) 섭식장애의 일종으로, 환자는 '배출형'과 '비배출형'의 두 가지 방법으로 체중 감량을 시도하는 경향이 있습니다. 구토와 같은 '배출'에는 식후 구토가 포함되며, 기타 '비배출'에는 금식, 관장기, 완하제나 이뇨제 사용, 과도한 운동 등이 포함됩니다. 신경성 폭식증은 치아와 잇몸의 부패, 심장질환, 자해행위, 탈수, 소화기 질환 등 생명을 위협하는 다양한 합병증을 유발할 수 있습니다.
시장 역학
연구기관들은 일반 대중에게 최신 섭식장애 치료법에 대한 인식을 확산시키기 위해 웹사이트 개설에 주력하고 있으며, 이는 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어 2018년 비영리단체인 ECRI랩은 환자와 보호자를 위한 신경성 폭식증 가이드 사이트를 개설했습니다. 이 웹사이트는 신경성 폭식증 치료에 대한 가이드라인과 최신 정보를 제공합니다.
연구기관은 섭식장애 치료에 있으며, 행동치료의 효과를 검증하기 위한 임상검사를 시행하고 있습니다. 예를 들어 2020년 11월 7일 미국 국립정신건강연구소(NIMH)는 신경성 폭식증 치료에서 인지행동치료의 효과를 확인하기 위해 임상실험에 참여할 신경성 폭식증 성인 여성 환자를 모집한다고 발표했습니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 매출 창출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계의 신경성 폭식증 치료 시장의 주요 기업 개요을 작성했습니다. 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 개발 및 전략, 향후 계획 등을 소개합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계의 신경성 폭식증 치료 시장 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 참가자, 금융 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 신경성 폭식증 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 쉽게 의사결정을 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 개요
제3장 시장 역학, 규제, 동향 분석
제4장 세계의 신경성 폭식증 치료 시장 : 치료법별, 2021-2033년
제5장 세계의 신경성 폭식증 치료 시장 : 투여 경로별, 2021-2033년
제6장 세계의 신경성 폭식증 치료 시장 : 유통 채널별, 2021-2033년
제7장 세계의 신경성 폭식증 치료 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 섹션
KSA 26.06.01Bulimia Nervosa Treatment Market is estimated to be valued at USD 644.8 Mn in 2026 and is expected to reach USD 964.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 644.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.20% | 2033 Value Projection: | USD 964.6 Mn |
Bulimia nervosa is a type of eating disorder, in which the person eat large amount of food (binge eating) within a short period of time, after which the person tends to lose weight by two ways: purging and non-purging. Purging includes vomiting post eating and non-purging includes fasting, enemas, use of laxatives and diuretics, and excessive exercising. Bulimia nervosa may lead to various life-threatening complications such as tooth & gum decay, heart problems, self-injury, dehydration, and digestive problems.
Market Dynamics
Research institutes are indulged in launching websites, in order to spread awareness about the latest eating disorders treatment options, among the population, which is expected to fuel growth of the market over the forecast period. For instance, in 2018, ECRI institute, a non-profit organization, launched a bulimia nervosa guide website for the patients and their caretakers. This website provide guidelines and latest information about the treatment options for the bulimia nervosa.
Research institutes are indulged in conducting clinical trials for finding the effectiveness of behavioral therapy for the treatment of eating disorders. For instance, on 7th November 2020, National Institute of Mental Health (NIMH) announced that, they are recruiting adult women patients suffering from bulimia nervosa for conducting clinical trials, in order to determine the effectiveness of cognitive behavioral therapy in the treatment of bulimia nervosa.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global bulimia nervosa treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global bulimia nervosa treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the bulimia nervosa treatment market
Market Segmentation
- By Treatment Type (Revenue, USD Mn, 2021-2033)
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- By Route of Administration (Revenue, USD Mn, 2021-2033)
- Oral
- Intravenous
- Others
- By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bulimia Nervosa Treatment Market, By Region: (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Allergan, Inc.
- Eli Lilly and Company
- AstraZeneca plc
- Alembic Pharmaceuticals Ltd
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Reddy's Laboratories Limited
- Lupin Pharmaceuticals, Inc.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Epidemiology
- Key Developments
- Regulatory Scenario
- PEST Analysis
- Product launches
- Acquisition and Merger Scenario
4. Global Bulimia Nervosa Treatment Market, By Treatment Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Drug Treatment
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-drug Treatment
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Nutritional Therapy
- Behavioral Therapy
- Others
5. Global Bulimia Nervosa Treatment Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Intravenous
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Bulimia Nervosa Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Bulimia Nervosa Treatment Market, By Region, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 - 2033
- North America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Company Profiles
- Allergan, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Alembic Pharmaceuticals Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson Services, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Reddy's Laboratories Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Lupin Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Aurobindo Pharma
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Apotex Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
- Allergan, Inc.
9. Section
- References
- Research Methodology
- About us and Sales Contact
